Schizophrenia – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034
Schizophrenia Emerging Therapy
Thelansis’s “Schizophrenia
Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To
2034″ provides a comprehensive analysis of the emerging competitive
landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL
insights on key emerging therapies and key drug development opportunities in
the indication.
Schizophrenia
Overview
Schizophrenia, a persistent and
debilitating brain disorder, is typically characterized by two sets of
symptoms: positive and negative. Those with schizophrenia often experience
symptoms that leave them feeling fearful and withdrawn, with their speech and
behavior becoming so disorganized that they can be incomprehensible or alarming
to others. The ICD-10 outlines diagnostic criteria for seven subtypes of
schizophrenia, which include Paranoid, Catatonic, Postschizophrenic Depression,
Simple, Hebephrenic, Undifferentiated, and Residual schizophrenia.
Schizophrenic disorders are thought to have a complex origin involving genetic,
environmental, and neurotransmitter pathophysiological factors. Diagnosing
schizophrenia involves a psychiatric assessment since no definitive test exists
for the condition. In the United States, diagnosis relies primarily on the
Diagnostic and Statistical Manual (DSM-V), while in Europe, the International
Classification of Diseases (ICD), 10th revision, is often used. Schizophrenia
necessitates lifelong treatment, even when symptoms abate. Management includes
medication and psychosocial therapy, with occasional hospitalization. Treatment
is typically guided by a psychiatrist experienced in schizophrenia care.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and
enriched by insights from interviews with leading KOLs
*Survey is
customized based on client requirements
Deliverables
format:
- PowerPoint presentation
- MS Excel
Key business
questions answered:
- Detailed emerging competitive
landscape
- Pipeline
analysis
- Target patients
for emerging therapies
- Key companies
- Key mechanism of
actions
- Launch date
estimates, etc.
- Clinical trial landscape analysis
- Target patient
segments
- Trial endpoints
- Trial design
- Recruitment
criteria, etc.
- Unmet Needs and Opportunities
- Performance of
key current therapies
- Top areas of
unmet needs
- Opportunity
sizing for key unmet needs
- Target Product Profiles
- Attributes and
levels
- Physician
likelihood of prescribing
- Expected patient
shares
- KOL insights on key emerging
therapies
- Level of
awareness
- Expected use /
line of therapy
- Extent to fulfil
key unmet needs
- KOL quotes
Read more: Schizophrenia – Emerging Therapy, with Unmet Needs and
TPP Insights Report – 2024 To 2034
Comments
Post a Comment